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Introduction 
Hidradenitis suppurativa (HS) is a skin condition 
characterized by chronic follicular occlusion 
located primarily in the axillary, groin, and 
perianal regions that can present with recurrent 
nodules, inflamed abscesses, and scarring [1]. The 
painful flare-ups and malodorous discharge can 
have a profoundly negative psychological impact 
on patients. Studies have consistently shown 
decreased quality of life among HS patients 
through measures such as the Dermatology Life 
Quality Index (DLQI), the Beck Depression 
Inventory (BDI), and the Patient Health 
Questionnaire-9 (PHQ-9), [2]. In addition, patients 
have associated comorbidities such as metabolic 
syndrome, inflammatory bowel disease, and 
depression [3]. The Short-Form-12 Health Survey 
(SF-12) is a rapid, effective way to assess health 
outcomes from the patient perspective. The SF-12 
measures physical health composite scores (PCS-
12) and mental health composite scores (MCS-
12), in which the population mean of each score 
is 50 with standard deviation of 10. In addition to 
psychosocial effects, HS has recently been 
demonstrated to have an association with joint 
pathology (e.g., spondyloarthropathy), [4]. 
Estimates of the prevalence of arthropathy in HS 
Abstract 
Hidradenitis suppurativa is characterized by 
chronic follicular occlusion that presents with 
recurrent nodules, inflamed abscesses, and 
scarring. Research has shown that these patients 
have a decreased quality of life. In addition to its 
psychosocial effects, hidradenitis suppurativa has 
recently been associated with joint pathology. In 
this study, we distributed a survey consisting of 
the Short Form 12 Health Survey, used for 
assessing health outcomes, along with additional 
questions about joint pain to an online 
hidradenitis suppurativa support group in order to 
understand the effect of comorbid arthralgia on 
quality of life in this disease. The respondents in 
this study had significantly reduced physical 
health composite scores-12 (PCS-12), (35.8 versus 
50, P<0.001) and mental health composite scores-
12 (MCS-12), (33.7 versus 50, P<0.001) scores 
compared to the general population. Additionally, 
patients reporting severe arthralgia had 
significantly lower PCS-12 (32.3 versus 36.5; 
P<0.05) and MCS-12 (33.3 versus 40.5; P<0.001) 
scores compared to those with mild arthralgia. 
Despite the effect of comorbid arthralgia on 
quality of life, only 11% reported having been 
asked about joint pain by their dermatologist. 
Routine screening questions concerning 
associated arthralgia and diminished quality of life 
may be helpful during clinician assessment and 
treatment of hidradenitis suppurativa patients. 
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range from 3 to 67% [5]. In this study, we sought 
to understand the prevalence of arthropathy in 
patients with hidradenitis suppurativa and its 
effect on quality of life. 
 
Methods 
We distributed a survey consisting of the SF-12 
along with supplemental questions about joint 
pain to an online group of HS patients. The mean 
PCS-12/MCS-12 of surveyed patients were 
compared to population means using a one-
sample t-test. The mean PCS-12/MCS-12 of 
patients who reported having joint pain “rarely” or 
“sometimes” (i.e., mild arthralgia) were compared 
to those of patients who reported having joint 
pain “often” or “almost always” (i.e., severe 
arthralgia) using a two-sample t-test. This 
research involved the use of human subjects and 
was approved by the institutional review board. 
 
Results 
Of 1083 group members who viewed the survey 
posting, 228 participants began the survey, and 
209 (19.3%) completed it. Survey respondents 
were predominantly female with a mean age of 
37.2 years. The patients in this study had 
significantly reduced PCS-12 (35.8 versus 50, 
P<0.001) and MCS-12 (33.7 versus 50, P<0.001) 
scores compared to the general population 
(Figure 1). When asked about frequency of joint 
pain, 36.8% of respondents reported experiencing 
pain “almost always,” 28.7% “often,” 26.3% 
“sometimes,” and 8.1% “rarely.” Hidradenitis 
suppurativa patients with severe arthralgia had 
significantly lower PCS-12 (32.3 versus 36.5, 
P<0.05) and MCS-12 (33.3 versus 40.5, P<0.001) 
scores compared to those with mild arthralgia 
(Figure 2). Previously diagnosed joint disease was 
reported by 28.7% of respondents; only 11.0% 
reported having been asked about joint pain by 
their dermatologist. 
 
Discussion 
We identified a significant decrease in quality of 
life in HS patients that is worsened by the 
presence of concurrent arthralgia, which appears 
to be more prevalent in this population [6]. 
Limitations of this study include lack of clinical 
confirmation of disease and response bias  
 
Figure 2. Physical health composite scores-12 (PCS-12) and 
mental health composite scores-12 (MCS-12) scores 
comparing hidradenitis suppurativa patients with mild and 
severe joint pain. Patients with severe arthralgia scored 
significantly lower in both PCS-12 and MCS-12 than those 
with mild joint pain. 
 
Figure 1. Physical health composite scores-12 (PCS-12) and 
mental health composite scores-12 (MCS-12) scores in 
hidradenitis suppurativa patients compared to the general 
population. Hidradenitis suppurativa patients scored 
significantly lower on PCS-12 and MCS-12 compared to the 
general population. 
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inherent in survey research. Since the severity of 
disease in each patient could not be measured, it 
is unclear whether the relationship between 
concurrent arthralgia and decreased quality of life 
is directly related to joint pain or is an indicator of 
more severe disease and systemic inflammation. 
Regardless of etiology, the association between 
HS, arthralgia, and diminished quality of life 
suggests that dermatologists should be routinely 
screening HS patients for joint pathology. In this 
survey, despite most patients experiencing 
frequent arthralgias, only 11% reported ever 
being asked about joint pain by their 
dermatologist. Questions concerning associated 
arthralgia and diminished quality of life may be 
helpful during clinician assessment of disease 
burden and may offer guidance in appropriate 
selection of treatment options. 
 
Conclusion 
Owing to the limited understanding of 
arthropathy in HS, there is a need for 
dermatologists to routinely ask about joint 
symptoms in HS patients, offer available 
therapeutics, or refer to a rheumatology 
consultant. 
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